Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

Medical experts have begun using ketamine, an old anesthesia drug with psychedelic qualities, to help with treatment-resistant depression, post-traumatic stress disorder and anxiety. Now, doctors are ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

Untreated mental health issues, like Treatment-Resistant Depression (TRD), cost U.S. businesses billions annually in lost ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...

So much time is spent banging on about recycling in grandiose abstract terms, yet cobblers are going out of business' ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is ...